Disialoganglioside GD3 (GD3)

Disialoganglioside GD3 is a glycosphingolipid composed of a ceramide backbone linked to a complex oligosaccharide head group containing two sialic acid residues[8]. It is highly expressed on the surface of neuroectoderm-derived tumors such as melanoma, neuroblastoma, and glioma, and can also be found in immature neural cells and certain immune cells[2][3][4]. GD3 plays diverse roles in biology, including the regulation of cell proliferation, differentiation, apoptosis, and immune suppression. Intracellular GD3 actively induces mitochondrial membrane permeabilization and promotes apoptosis, whereas its expression in the tumor microenvironment influences immune responses and supports tumor growth and metastasis[1][3][5][8]. GD3 serves as a clinically relevant tumor-associated antigen and is targeted by monoclonal antibodies in experimental immunotherapy, particularly against melanoma and glioma[2][4]. Its recognition by both the humoral and innate immune system has prompted strategies such as ADCC and complement-mediated cytotoxicity for cancer treatment[2][7]. Notably, GD3 is the biosynthetic product of GD3 synthase (GD3S), and its expression is regulated by the ST8SIA1 gene[3]. Safety concerns include potential toxicities from targeting GD3 due to low but detectable expression in certain normal tissues and risks of non-specific immune activation. There are currently no approved small-molecule drugs targeting GD3; most clinical development focuses on monoclonal antibodies or immunotherapeutic approaches[4][2].

Other names

GD3 gangliosideGanglioside G3Aalpha-N-Acetylneuraminyl-2,8-alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-glucosyl-1,1’-ceramide

Antibody-dependent cellular cytotoxicity (ADCC), Complement-dependent cytotoxicity, Immune modulation, Induction of apoptosis